Advanced Biological Laboratories (ABL) has acquired all the assets of Evivar Medical (Evivar), which includes its Hepatitis B virus (HBV) and C (HCV) web-based decision support tools and the associated viral genome analysis systems (SeqHepB and SeqHepC), intellectual property portfolio, and all associated commercial arrangements.
ABL president and CEO Chalom Sayada said the acquisition of Evivar Medical assets will add value and will allow ABL to further expand its Virology portfolio from HIV to include Hepatitis disease management.
"The interface between TherapyEdge®, ViroScore®, DeepChek® and the SeqHepB/C systems is an important milestone for ABL’s platform that enables clinicians to manage complex treatment and diagnostics decisions, optimize and provide individualized care," said Sayada.
"Evivar’s expertise in disease management platform for Hepatitis B and C is a complementary addition to ABL’s infectious diseases management technologies and builds on our commitment to deliver innovative, best-in-class tools."
ABL will leverage its experience in HIV disease management and expand into the field of viral hepatitis.
Evivar Medical CEO Bernie Romanin stated, "We are excited about this transaction because the combined platforms builds on both companies’ technological strengths to further enhance disease management tools for major viral infections including complex management of co-infected individuals."
Evivar has partnered with an extensive range of companies worldwide including the largest National Reference Laboratories in the US, Global Diagnostics Companies and specialty Hepatitis clinical centres.